NCT05553522 2025-12-31
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Baptist Health South Florida
Phase 1 Terminated
Clinical Trials
5 trialsNCT05868226 2025-04-04
PRE-I-SPY-PI
QuantumLeap Healthcare Collaborative
Phase 1 Recruiting
NCT06162559 2024-01-11
TRAIN-4
The Netherlands Cancer Institute
Phase 1 Recruiting
NCT06067776 2023-10-05
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
University of California, Davis
Phase 1 Not yet recruiting
NCT03846583 2020-10-23
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Dana-Farber Cancer Institute
Phase 1 Withdrawn